If you’ve treated patients with chronic spontaneous urticaria (CSU), you know how frustratingly persistent the itching and hives can be - and how urgently patients seek relief. A new pooled analysis from the phase 3 REMIX-1 and REMIX-2 trials offers an encouraging advance: the oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib delivers rapid symptom improvement within the first day of treatment.
Researchers analyzed daily Urticaria Activity Scores (UAS; range 0–6), capturing both hive count and itch severity, among over 900 participants (remibrutinib 25 mg twice daily, n = 606; placebo, n = 306). At baseline, both groups had similar UAS values (≈4.4), reflecting moderate disease activity.
Remarkably, remibrutinib-treated patients experienced improvement within 12 hours of the first dose, with mean UAS dropping faster than placebo (3.96 vs. 3.99). By day 7, daily UAS decreased to 2.25 with remibrutinib versus 3.49 on placebo. Moreover, the proportion of patients achieving little-to-no symptoms (UAS 0–1) rose sharply - from 1.3% at baseline to 37% after one week, compared with only 9.7% on placebo.
These findings highlight remibrutinib’s rapid and sustained symptom control, setting it apart as a promising option for patients who need faster relief from the burdens of CSU.
References:
https://www.sciencedirect.com/science/article/pii/S009167492501228X